Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Metrics to compare | TPST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTPSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −4.4x | −0.6x | |
PEG Ratio | −0.01 | 0.05 | 0.00 | |
Price/Book | 2.1x | 3.0x | 2.6x | |
Price / LTM Sales | - | 84.0x | 3.4x | |
Upside (Analyst Target) | 239.6% | 46.7% | 41.3% | |
Fair Value Upside | Unlock | 1.7% | 4.9% | Unlock |